Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer

Summary

This phase I/II trial studies the side effects and best dose of mercaptopurine, and to see how well it works in treating patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC). HLRCC is a rare inherited disorder that increases the risk of developing benign (not cancer) tumors of the skin and the uterus (leiomyomas) and malignant (cancer) tumors of the uterus (leiomyosarcoma) and the kidney. Mercaptopurine is in a class of medications called purine antagonists. It works by stopping the growth of cancer cells.

Conditions

• Advanced Kidney Carcinoma
• Advanced Renal Cell Carcinoma
• Hereditary Leiomyomatosis and Renal Cell Carcinoma
• Metastatic Kidney Carcinoma
• Metastatic Renal Cell Carcinoma
• Skin Leiomyoma
• Stage III Renal Cell Cancer AJCC v8
• Stage IV Renal Cell Cancer AJCC v8
• Uterine Corpus Leiomyoma

Interventions

DRUG

Mercaptopurine

Given PO

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Skin Biopsy

Undergo skin biopsy

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood

Sponsors & Collaborators

• The V Foundation

  collaborator OTHER

• Phase One Foundation

  collaborator OTHER

• Jonsson Comprehensive Cancer Center

  lead OTHER

Principal Investigators

• Brian Shuch · UCLA / Jonsson Comprehensive Cancer Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-12-01

Primary Completion

2034-12-01

Completion

2035-12-01

FDA Drug

Yes

Countries

• United States

Study Locations